Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
Investigational New Drugs
|
March 14, 2024
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
Maxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, et al.
Cancer
|
May 10, 2005
Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters
Burcak Vural, Lin-Chi Chen, Pinar Saip, et al.
Investigational New Drugs
|
April 11, 2023
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors
Anastasios Stathis, Anthony W Tolcher, Judy S Wang, et al.
Cancer Chemotherapy and Pharmacology
|
June 28, 2011
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
Paul Hamberg, Margaret M Woo, Lin-Chi Chen, et al.
Biomaterials Science
|
August 12, 2015
Tunable coverage of immobilized biomolecules for biofunctional interface design
Jyun-Ting Wu, Ting-Pi Sun, Chao-Wei Huang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 3, 2007
Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels
Lee M Krug, Daniel T Milton, Achim A Jungbluth, et al.
British Journal of Haematology
|
April 10, 2015
MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia
Hua Zhong, Gong Chen, Lori Jukofsky, et al.
Investigational New Drugs
|
June 28, 2021
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
Antoine Italiano, Wilson H Miller, Jean-Yves Blay, et al.
The Journal of Experimental Medicine
|
March 29, 2007
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy
Radek Spisek, Anjli Kukreja, Lin-Chi Chen, et al.
Electrophoresis
|
February 8, 2011
A novel DNA selection and direct extraction process and its application in DNA recombination
An-Bang Wang, Chia-Wei Cheng, I-Chun Lin, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
Investigational New Drugs
|
March 14, 2024
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
Maxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, et al.
Cancer
|
May 10, 2005
Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters
Burcak Vural, Lin-Chi Chen, Pinar Saip, et al.
Investigational New Drugs
|
April 11, 2023
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors
Anastasios Stathis, Anthony W Tolcher, Judy S Wang, et al.
Cancer Chemotherapy and Pharmacology
|
June 28, 2011
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
Paul Hamberg, Margaret M Woo, Lin-Chi Chen, et al.
Biomaterials Science
|
August 12, 2015
Tunable coverage of immobilized biomolecules for biofunctional interface design
Jyun-Ting Wu, Ting-Pi Sun, Chao-Wei Huang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 3, 2007
Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels
Lee M Krug, Daniel T Milton, Achim A Jungbluth, et al.
British Journal of Haematology
|
April 10, 2015
MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia
Hua Zhong, Gong Chen, Lori Jukofsky, et al.
Investigational New Drugs
|
June 28, 2021
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
Antoine Italiano, Wilson H Miller, Jean-Yves Blay, et al.
The Journal of Experimental Medicine
|
March 29, 2007
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy
Radek Spisek, Anjli Kukreja, Lin-Chi Chen, et al.
Electrophoresis
|
February 8, 2011
A novel DNA selection and direct extraction process and its application in DNA recombination
An-Bang Wang, Chia-Wei Cheng, I-Chun Lin, et al.
Page
of 5